K Number
K122836
Device Name
AFFIRM BREAST BIOPSY GUIDANCE SYSTEM
Date Cleared
2013-01-11

(116 days)

Product Code
Regulation Number
892.1710
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Affirm breast biopsy guidance system is an optional accessory for the Selenia Dimensions Mammography System. It is designed to allow the accurate localization of lesions in the breast in three dimensions. It is intended to provide guidance for interventional purposes (such as biopsy, pre-surgical localization or treatment devices).
Device Description
The Affirm Breast Biopsy Guidance System is used with Selenia Dimensions 2D or with Selenia Dimensions 3D tomosynthesis. Lesion location can be obtained from either 2D stereotactic or 3D tomosynthesis image acquisition. Both stereotactic and 3D localization calculate a three dimensional location for percutaneous placement for biopsy, pre-surgical localization or treatment devices. Safety Features include: Automatic detection of mounting, latching, and connection of biopsy guidance module; C-arm motion disabled if biopsy guidance module is not locked in place; Automatic compression release disabled when biopsy guidance module installed; Motorized movement of biopsy device only under user control; Audible alert if biopsy device motion could result in mechanical interference.
More Information

No
The document describes a mechanical guidance system for breast biopsy and does not mention any AI or ML components.

No
The device is described as an "optional accessory" for a mammography system designed to help localize breast lesions for interventional purposes like biopsy or pre-surgical localization. It does not exert a therapeutic effect on the patient.

No
Explanation: The device is described as a guidance system for interventional purposes (biopsy, pre-surgical localization, treatment devices) and localizes lesions. It does not diagnose disease itself.

No

The device description explicitly states it is an "optional accessory" for a mammography system and details hardware components and safety features related to mechanical movement and physical attachment (e.g., "biopsy guidance module," "C-arm motion," "Motorized movement of biopsy device"). This indicates it is a hardware device with integrated software, not a software-only device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly states that the system is designed for localization of lesions in the breast in three dimensions and to provide guidance for interventional purposes such as biopsy, pre-surgical localization, or treatment devices. This describes a device used for imaging and procedural guidance within the body, not for testing samples in vitro (outside the body).
  • Device Description: The description focuses on the mechanical and imaging aspects of the system used for guiding procedures on the breast. It describes how it works with mammography systems and provides safety features related to the physical guidance mechanism.
  • Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), reagents, or any other components typically associated with in vitro diagnostic testing.

In summary, the Affirm breast biopsy guidance system is a medical device used for image-guided intervention, which is distinct from an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The Affirm breast biopsy guidance system is an optional accessory for the Selenia Dimensions Mammography System. It is designed to allow the accurate localization of lesions in the breast in three dimensions. It is intended to provide guidance for interventional purposes (such as biopsy, pre-surgical localization or treatment devices).

Product codes

90 IZH

Device Description

The Affirm Breast Biopsy Guidance System is used with Selenia Dimensions 2D or with Selenia Dimensions 3D tomosynthesis. Lesion location can be obtained from either 2D stereotactic or 3D tomosynthesis image acquisition.

Both stereotactic and 3D localization calculate a three dimensional location for percutaneous placement for biopsy, pre-surgical localization or treatment devices.

Safety Features include:

  • Automatic detection of mounting, latching, and connection of biopsy guidance . module
  • C-arm motion disabled if biopsy guidance module is not locked in place ●
  • Automatic compression release disabled when biopsy guidance module installed .
  • Motorized movement of biopsy device only under user control
  • Audible alert if biopsy device motion could result in mechanical interference ●

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

2D stereotactic or 3D tomosynthesis image acquisition (from Selenia Dimensions 2D or Selenia Dimensions 3D tomosynthesis)

Anatomical Site

Breast

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

The Affirm Breast Biopsy Guidance System meets IEC 60601-2-45 Medical Electrical Equipment - Safety of Mammographic X-ray Equipment and Mammographic Stereotactic Devices. Hologic successfully performed design control verification and validation tests in accordance with 21 CFR Part 820.

Key Metrics

Not Found

Predicate Device(s)

K103512

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.1710 Mammographic x-ray system.

(a)
Identification. A mammographic x-ray system is a device intended to be used to produce radiographs of the breast. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.

0

Hologic, Inc.

K122836

Modified Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification

510(k) Summary

JAN 1 1 2013

This 510(k) summary is submitted in accordance with the requirements of 21 CFR Part 807.92

Product Name: Affirm Breast Biopsy Guidance System

Product Classification Name: Mammographic X-Ray System

Product Classification Code: 90 IZH CFR Section: 892.1710

Classification Panel: · Radiology Class II

Manufacturer: Hologic, Inc. 36-37 Apple Ridge Road Danbury, CT 06810 USA

Contact Person:Gail Yaeker-Daunis
Telephone Number:(203) 731-8337
Fax Number:(203) 731-8440

Date Prepared: August 14, 2012

Predicate Device: Affirm Breast Biopsy Guidance System, K103512

Device Description:

The Affirm Breast Biopsy Guidance System is used with Selenia Dimensions 2D or with Selenia Dimensions 3D tomosynthesis. Lesion location can be obtained from either 2D stereotactic or 3D tomosynthesis image acquisition.

Both stereotactic and 3D localization calculate a three dimensional location for percutaneous placement for biopsy, pre-surgical localization or treatment devices.

Safety Features include:

  • Automatic detection of mounting, latching, and connection of biopsy guidance . module
  • C-arm motion disabled if biopsy guidance module is not locked in place ●
  • Automatic compression release disabled when biopsy guidance module installed .
  • Motorized movement of biopsy device only under user control �
  • Audible alert if biopsy device motion could result in mechanical interference ●

Indications for Use:

1

Hologic, Inc.

Modified Affirm Breast Biopsy Guidance System Special 510(k) Premarket Notification

The Affirm Breast Biopsy Guidance System is an optional accessory for the Selenia Dimensions Mammography System. It is designed to allow the accurate localization of lesions in the breast in three dimensions. It is intended to provide guidance for interventional purposes (such as biopsy, pre-surgical localization or treatment devices).

Comparison with Predicate Devices:

The modified Affirm Breast Biopsy Guidance System is substantially equivalent to Affirm Breast Biopsy Guidance System which was cleared as K103512 for use with the Selenia Dimensions 2D Mammography system to provide localization of areas of concern for performance of breast biopsies. The intended use is the same using either stereotactic or 3D tomosynthesis lesion localization for biopsy with Selenia Dimensions Mammography System.

Summary of Testing:

The Affirm Breast Biopsy Guidance System meets IEC 60601-2-45 Medical Electrical Equipment - Safety of Mammographic X-ray Equipment and Mammographic Stereotactic Devices. Hologic successfully performed design control verification and validation tests in accordance with 21 CFR Part 820.

Conclusion:

The Affirm Breast Biopsy Guidance System's design, operation, construction and materials are unchanged from the cleared Affirm Breast Biopsy Guidance System. A software change enables use of either stereotactic or 3D tomosynthesis calculations for lesion localization for biopsy when the Affirm is used with a Selenia Dimensions 3D system . There is no change to the device when used with the Selenia Dimensions 2D system. Accuracy can be verified during the biopsy process. The 3D tomosynthesis lesion location is substantially equivalent to and as safe and effective as the cleared Affirm Breast Biopsy Guidance System and poses no additional risks or hazards.

2

Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the left side of the emblem.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

January 11, 2013

Ms. Gail Yaeker-Daunis Senior Regulatory Specialist Hologic, Inc. 36 Apple Ridge Road DANBURY CT 06810

Re: K122836

Trade/Device Name: Affirm Breast Biopsy Guidance System Regulation Number: 21 CFR 892.1710 Regulation Name: Mammographic x-ray system Regulatory Class: II Product Code: IZH Dated: December 14, 2012 Received: December 17, 2012

Dear Ms. Yaeker-Daunis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

3

Page 2-Ms. Yaeker-Daunis

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number 1-800- 638-2041 or 301-796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Sean M. Boyd -S for

Janine M. Morris Director. Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure .

4

Indications for Use

510(k) Number (if known): K122836

Device Name:

Affirm Breast Biopsy Guidance System

Indications for Use:

The Affirm breast biopsy guidance system is an optional accessory for the Selenia Dimensions Mammography System. It is designed to allow the accurate localization of lesions in the breast in three dimensions. It is intended to provide guidance for interventional purposes (such as biopsy, pre-surgical localization or treatment devices).

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Sean M. Boyd -S

(Division Sign Off) Division of Radiological Health Office of In Vitro Diagnostic and Radiological Health

510(k) K122836

Page 1 of 1